Volume 11, Number 6—June 2005
Dispatch
Macrolide- and Telithromycin-resistant Streptococcus pyogenes, Belgium, 1999–20031
Surbhi Malhotra-Kumar*
, Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
, Christine Lammens*, Sabine Chapelle*, Monique Wijdooghe*, Jasper Piessens*, Koen Van Herck*, and Herman Goossens*
Table A2
Temporal changes in pulsed-field gel electrophoresis (PFGE) and emm type distribution among 3 macrolide-resistant Streptococcus pyogenes phenotypes
| Macrolide-resistant phenotype | Emm type | PFGE cluster* | Frequency (n=506) | No. (%) of macrolide-resistant S. pyogenes |
||||
|---|---|---|---|---|---|---|---|---|
| 1999 (n=81) | 2000 (n=41) | 2001 (n=73) | 2002 (n=215) | 2003 (n=96) | ||||
| cMLS | emm22 | 1 | 70 | 45 (56) | 7 (17) | 9 (12) | 7 (3) | 2 (2) |
| 1057 | 1 | 1 (0.4) | ||||||
| emm4 | 10 | 9 | 9 (12) | |||||
| 11 | 8 | 3 (4) | 2 (3) | 2 (1) | 1 (1) | |||
| 1002 | 1 | 1 (1) | ||||||
| 1009 | 2 | 2 (5) | ||||||
| emm76 | 32 | 1 | 1 (1) | |||||
| emm2 | new2 | 1 | 1 (2) | |||||
| emm28 | 4 | 45 | 4 (5) | 15 (7) | 26 (27) | |||
| emm11 | 23 | 28 | 1 (1) | 6 (3) | 21 (22) | |||
| emm75 | 15 | 1 | 1 (1) | |||||
| emm6 | 5 | 1 | 1 (1) | |||||
| emm12 | 6 | 1 | 1 (1) | |||||
| 57 | 11 | 8 (4) | 3 (3) | |||||
| emm77 | 10 | 6 | 6 (3) | |||||
| NT† | 2 | 3 | 3 (1) | |||||
| 49 | 12 | 12 (6) | ||||||
| 64 | 4 | 4 (2) | ||||||
| 65 | 1 | 1 (0.4) | ||||||
| 69 | 2 | 2 (1) | ||||||
| 70 | 1 | 1 (0.4) | ||||||
| M | emm1 | 1001 | 128 | 7 (9) | 12 (29) | 23 (32) | 80 (37) | 6 (6) |
| 1022 | 2 | 2 (2) | ||||||
| 3 | 1 | 1 (1) | ||||||
| emm12 | 6 | 1 | 1 (0.4) | |||||
| 1011 | 10 | 4 (5) | 2 (5) | 3 (4) | 1 (0.4) | |||
| 1025 | 10 | 3 (4) | 2 (1) | 5 (5) | ||||
| 1026 | 2 | 2 (2) | ||||||
| 1027 | 1 | 1 (1) | ||||||
| 1030 | 2 | 1 (2) | 1 (0.4) | |||||
| 1035 | 9 | 1 (1) | 4 (2) | 4 (4) | ||||
| 1044 | 1 | 1 (0.4) | ||||||
| 1047 | 2 | 2 (1) | ||||||
| emm2 | 18 | 1 | 1 (1) | |||||
| 1038 | 1 | 1 (1) | ||||||
| new 3 | 1 | 1(1) | ||||||
| 1042 | 1 | 1 (0.4) | ||||||
| 1034 | 1 | 1 (1) | ||||||
| 1049 | 1 | 1 (0.4) | ||||||
| emm4 | 1002 | 28 | 2 (2.5) | 2 (5) | 7 (10) | 7 (3) | 10 (10) | |
| 1007 | 2 | 2 (5) | ||||||
| 1008 | 1 | 1 (1) | ||||||
| 1009 | 1 | 1 (2) | ||||||
| 1010 | 11 | 1 (1) | 3 (7) | 2 (3) | 2 (1) | 3 (3) | ||
| 1019 | 1 | 1 (1) | ||||||
| 1021 | 2 | 2 (2) | ||||||
| 1043 | 1 | 1 (0.4) | ||||||
| 1044 | 3 | 3 (3) | ||||||
| 1054 | 2 | 2 (1) | ||||||
| 1059 | 1 | 1 (0.4) | ||||||
| emm77 | 1028 | 4 | 4 (10) | |||||
| 9 | 2 | 1 (2) | 1 (1) | |||||
| 10 | 3 | 3 (1) | ||||||
| emm75 | 1036 | 1 | 1 (1) | |||||
| 1060 | 1 | 1 (0.4) | ||||||
| emm33 | 1046 | 2 | 2 (1) | |||||
| 1052 | 2 | 2 (1) | ||||||
| emm78 | 1042 | 1 | 1 (0.4) | |||||
| emm28 | 1033 | 1 | 1 (1) | |||||
| emm9 | 1042 | 2 | 2 (2) | |||||
| emm60 | 8 | 1 | 1 (1) | |||||
| NT | 42 | 1 | 1 (1) | |||||
| 1018 | 1 | 1 (2) | ||||||
| 62 | 3 | 3 (1) | ||||||
| 71 | 1 | 1 (0.4) | ||||||
| 1005 | 2 | 2 (1) | ||||||
| 1012 | 2 | 2 (1) | ||||||
| 1033 | 2 | 2 (1) | ||||||
| 1042 | 1 | 1 (0.4) | ||||||
| 1043 | 3 | 3 (1) | ||||||
| 1044 | 3 | 3 (1) | ||||||
| 1045 | 1 | 1 (0.4) | ||||||
| 1049 | 3 | 3 (1) | ||||||
| 1050 | 1 | 1 (0.4) | ||||||
| 1051 | 1 | 1 (0.4) | ||||||
| 1055 | 1 | 1 (0.4) | ||||||
| 1058 | 1 | 1 (0.4) | ||||||
| 1061 | 2 | 2 (2) | ||||||
| 83 | 1 | 1 (1) | ||||||
| 26 | 1 | 1 (1) | ||||||
| iMLS | emm1 | 1031 | 1 | 1 (2) | ||||
| emm22 | 1 | 2 | 2 (3) | |||||
| emm4 | 10 | 1 | 1 (1) | |||||
| emm9 | 61 | 1 | 1 (1) | |||||
| emm77 | 9 | 2 | 1 (1) | 1 (0.4) | ||||
| 10 | 1 | 1 (0.4) | ||||||
| 50 | 2 | 1 (1) | 1 (0.4) | |||||
| emm12 | 57 | 1 | 1 (0.4) | |||||
| emm18 | 1048 | 1 | 1 (0.4) | |||||
| emm89 | 77 | 1 | 1 (1) | |||||
| NT | new 1 | 1 | 1 (2) | |||||
| 63 | 1 | 1 (0.4) | ||||||
| 49 | 3 | 3 (3) | ||||||
*PFGE profile numbers from 1-100 designate restriction with SmaI and above 1,000 restriction profiles generated with SfiI.
†NT, non-typeable.
1A preliminary account of this work was presented at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 30–November 2, 2004, Washington DC, USA.
Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.